Human heart β-adrenoceptors: β1-adrenoceptor diversification through 'affinity states' and polymorphism

Clinical and Experimental Pharmacology and Physiology

Volumn 34, Issue 10, 2007, Pages 1020-1028

  Molenaar, P ^a,d   Chen, L ^a   Semmler, A B T ^a   Parsonage, W A ^b   Kaumann, A J ^c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d THE PRINCE CHARLES HOSPITAL   (Australia)

Author keywords

adrenoceptor polymorphism; adrenoceptor G sa protein coupling; 1 adrenoceptor affinity states; ( ) CGP 12177; Hastening of relaxation; Human heart adrenoceptors; Human heart failure; Phosphodiesterase enzymes

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; 5 [2 [[2 HYDROXY 3 [4 (1 METHYL 4 TRIFLUOROMETHYL 2 IMIDAZOLYL)PHENOXY]PROPYL]AMINO]ETHOXY]SALICYLAMIDE; ADRENALIN; BETA 1 ADRENERGIC RECEPTOR; BETA 1H ADRENERGIC RECEPTOR; BETA 1L ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; CILOSTAMIDE; CYCLIC AMP; FLUOXETINE; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; ISOBUTYLMETHYLXANTHINE; ISOPRENALINE; METOPROLOL; NORADRENALIN; PAROXETINE; PINDOLOL; PINDOLOL DERIVATIVE; PROPRANOLOL; RECEPTOR SUBTYPE; ROLIPRAM; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; BINDING AFFINITY; CARDIOMYOPATHY; CONFERENCE PAPER; CONGESTIVE CARDIOMYOPATHY; DRUG EFFICACY; GENETIC POLYMORPHISM; HEART ATRIUM; HEART CONTRACTION; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE; HEART MUSCLE RELAXATION; HEART VENTRICLE; HETEROZYGOTE; HUMAN; INOTROPISM; ISCHEMIC HEART DISEASE; KNOCKOUT MOUSE; LIGAND BINDING; NONHUMAN; ORTHOSTATIC HYPOTENSION; PHARMACOGENETICS; RADIOASSAY; RECEPTOR BINDING; RECEPTOR GENE; SYNCOPE; TREATMENT OUTCOME;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; HEART; HEART ATRIA; HEART VENTRICLES; HUMANS; MYOCARDIUM; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2; SPECIES SPECIFICITY;

EID: 34547966274     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2007.04730.x     Document Type: Conference Paper

References (81)

1. 2-Adrenoceptor activation by zinterol causes protein phosphorylation, contractile effects and relaxant effects through a cAMP pathway in human atrium. Mol. Cell. Biochem. 1996 163/164 : 113 23.
2. 2- adrenergic receptors hastens relaxation and mediates phosphorylation of phospholamban, troponin I, and C-protein in ventricular myocardium from patients with terminal heart failure. Circulation 1999 99 : 65 72.
3. s-protein. Circulation 2000 102 : 1814 21.
4. 2-adrenoceptors in human atrial myocardium from non-failing and failing hearts, consistent with Gs coupling but not with Gi coupling. Naunyn Schmiedebergs Arch. Pharmacol. 2007 375 : 11 28.
5. 1-adrenoceptor in human atrium and recombinant receptors. Naunyn Schmiedebergs Arch. Pharmacol. 2003 368 : 496 503.
6. Kaumann AJ. (-)-CGP 12177-induced increase of human atrial contraction through a putative third β-adrenoceptor. Br. J. Pharmacol. 1996 117 : 93 8.
7. 1-adrenoceptor. Naunyn Schmiedebergs Arch. Pharmacol. 2003 367 : 10 21.
8. Kaumann AJ, Molenaar P. Modulation of human cardiac function through four β-adrenoceptor populations. Naunyn Schmiedebergs Arch. Pharmacol. 1997 355 : 667 81.
9. 4-adrenoceptor' in mammalian heart. Clin. Exp. Pharmacol. Physiol. 1997 24 : 647 56.
10. 4-adrenoceptor pharmacology. Naunyn Schmiedebergs Arch. Pharmacol. 2001 363 : 87 93.
11. Kaumann AJ. Gs-coupled receptors in human heart. In : Kenakin T, Angus JA (eds). The Pharmacology of Functional, Biochemical, and Recombinant Receptor Systems. Handbook of Experimental Pharmacology. Springer, Berlin. 2000 : 73 116.
12. Kaumann AJ. Is there a third heart β-adrenoceptor? Trends Pharmacol. Sci. 1989 10 : 316 20.
13. 3H]-CGP 12177 binding. Br. J. Pharmacol. 1999 128 : 1445 60.
14. 1- adrenoceptors and interaction with β-blockers. Naunyn Schmiedebergs Arch. Pharmacol. 2004 369 : 525 32.
15. Molenaar P, Parsonage WA. Fundamental considerations of β-adrenoceptor subtypes in human heart failure. Trends Pharmacol. Sci. 2005 26 : 368 75.
16. Lechat P, Escolano S, Golmard JL et al. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS). Circulation 1997 96 : 2197 205.
17. O'Keefe JH, Magalski A, Stevens TL et al. Predictors of improvement in left ventricular ejection fraction with carvedilol for congestive heart failure. J. Nucl. Cardiol. 2000 7 : 3 7.
18. 1-adrenoceptor. Proc. Aust. Health Med. Res. Congr. 2006 248 (Abstract).
19. Buxton BF, Jones CR, Molenaar P, Summers RJ. Characterization and autoradiographic localization of β-adrenoceptor subtypes in human cardiac tissues. Br. J. Pharmacol. 1987 92 : 299 310.
20. 2- adrenoceptors in the human atrioventricular conducting system: A comparison of patients with idiopathic dilated cardiomyopathy and ischemic heart disease. J. Mol. Cell. Cardiol. 1994 26 : 313 23.
21. 2-adrenoceptors in human atrial myocardium. Circ. Res. 1990 66 : 1610 23.
22. 1-adrenergic receptor polymorphisms in human right atrium in vitro. J. Am. Coll. Cardiol. 2002 40 : 1275 82.
23. 1-adrenoceptors in human heart. Cardiovasc. Res. 2006 69 : 128 39.
24. 2-adrenoceptors of human heart. Differential antagonism of the positive inotropic effects and adenylate cyclase stimulation by (-)-noradrenaline and (-)-adrenaline. Naunyn Schmiedebergs Arch. Pharmacol. 1985 331 : 60 70.
25. Kaumann AJ, Hall JA, Murray KJ, Wells FC, Brown MJ. A comparison of the effects of adrenaline and noradrenaline on human heart: The role of beta 1- and beta 2-adrenoceptors in the stimulation of adenylate cyclase and contractile force. Eur. Heart J. 1989 10 (Suppl. B 29 7.
26. 3- adrenoceptors. Br. J. Pharmacol. 1997 120 : 165 76.
27. 2-adrenergic receptors. Proc. Natl Acad. Sci. USA 1993 90 : 10 798 802.
28. 2-adrenergic receptor coupling and sequestration. J. Biol. Chem. 1994 269 : 26 215 19.
29. Mundiña-Weilenmann C, Vitone L, Ortale M, de Cingolani GC, Mattiazzi A. Immunodetection of phosphorylation sites gives new insights into the mechanisms underlying phospholamban phosphorylation in the intact heart. J. Biol. Chem. 1996 271 : 33 561 7.
30. 17 in cardiac physiological and pathological conditions. Cardiovasc. Res. 2005 68 : 366 75.
31. Gupta RC, Neumann J, Watanabe AM, Sabbah NH. Inhibition of type 1 protein phosphatase activity by activation of β-adrenoceptors in ventricular myocardium. Biochem. Pharmacol. 2002 63 : 1069 76.
32. Tada M, Inui M, Yamada M et al. Effects of phospholamban phosphorylation catalyzed by adenosine 3′,5′-monophosphate- and calmodulin-dependent protein kinases on calcium transport ATPase of cardiac sarcoplasmic reticulum. J. Mol. Cell. Cardiol. 1983 15 : 335 46.
33. 2+ transport by cyclic-3′,5′-AMP-dependent and calcium-calmodulin-dependent phosphorylation of cardiac sarcoplasmic reticulum. Biochim. Biophys. Acta 1985 844 : 193 9.
34. Koss KL, Kranias EG. Phospholamban: A prominent regulator of myocardial contractility. Circ. Res. 1996 79 : 1059 63.
35. Kranias EG, Garvey JL, Srivastava RD, Solaro RJ. Phosphorylation and functional modifications of sarcoplasmic reticulum and myofibrils in isolated rabbit hearts stimulated with isoprenaline. Biochem. J. 1985 226 : 113 21.
36. Mittmann K, Jaquet K, Heilmeyer Jr. LMG. A common motif of two adjacent phosphoserines in bovine, rabbit and human cardiac troponin I. FEBS Lett. 1990 273 : 41 5.
37. Reiffert SU, Jaquet K, Heilmeyer LMG, Herberg FW. Stepwise subunit interaction changes by mono- and bisphosphorylation of cardiac troponin I. Biochemistry 1998 37 : 13 516 25.
38. Weisberg A, Winegrad S. Alteration of myosin cross bridges by phosphorylation of myosin-binding protein C in cardiac muscle. Proc. Natl Acad. Sci. USA 1996 93 : 8999 9003.
39. 1- adrenoceptors in human atrial myocardium. Naunyn Schmiedebergs Arch. Pharmacol. 2006 374 : 249 53.
40. 1-adrenoceptors, are reduced by PDE3 in human atrium but PDE4 in CHO cells. Naunyn Schmiedebergs Arch. Pharmacol. 2007 375 : 123 31.
41. Bokník P, Unkel C, Kirchhefer U et al. Regional expression of phospholamban in the human heart. Cardiovasc. Res. 1999 42 : 67 76.
42. Li J, Wang J, Russell FD, Molenaar P. Activation of calcineurin in human failing heart ventricle by endothelin-1, angiotensin II and urotensin II. Br. J. Pharmacol. 2005 145 : 432 40.
43. Morano I. Tuning the human heart molecular motors by myosin light chains. J. Mol. Med. 1999 77 : 544 55.
44. 2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes. Mol. Pharmacol. 1995 47 : 322 9.
45. 2- adrenoceptor to Gi proteins and its physiological relevance in murine cardiac myocytes. Circ. Res. 1999 84 : 43 52.
46. Zheng M, Zhu W, Han Q, Xiao RP. Emerging concepts and therapeutic implications of β-adrenergic receptor subtype signaling. Pharmacol. Ther. 2005 108 : 257 68.
47. 2+ dynamics, contractility, or phospholamban phosphorylation. J. Biol. Chem. 1994 269 : 19 151 6.
48. 2-adrenoceptor-mediated positive inotropic effect possibly unrelated to cyclic AMP. Naunyn Schmiedebergs Arch. Pharmacol. 1991 344 : 56 69.
49. 2-adrenoceptors in sheep cardiac ventricular muscle. J. Mol. Cell. Cardiol. 1992 24 : 753 64.
50. Blinks JR. Field stimulation as a means of effecting the graded release of autonomic transmitters in isolated heart muscle. J. Pharmacol. Exp. Ther. 1966 151 : 221 35.
51. Kaumann AJ. Cardiac β receptors: Experimental aspects. Z. Kardiol. 1983 72 : 63 83.
52. Arch. JR, Kaumann AJ. Beta3 and atypical beta-adrenoceptors. Med. Res. Rev. 1993 13 : 663 729.
53. 1-adrenergic receptors. J. Recept. Signal Transduct. Res. 1996 16 : 1 23.
54. 1-adrenoceptor. Mol. Pharmacol. 2003 63 : 1312 21.
55. 3-adrenergic-independent effects of CGP 12177 in brown adipose tissue. Mol. Pharmacol. 2000 57 : 252 8.
56. Molenaar P. The 'state' of β-adrenoceptors. Br. J. Pharmacol. 2003 140 : 1 2.
57. Kaumann AJ, Lobnig BM. Mode of action of (-)-pindolol on feline and human myocardium. Br. J. Pharmacol. 1986 89 : 207 18.
58. 1-adrenoceptor in ferret ventricular myocardium. Br. J. Pharmacol. 2002 135 : 451 61.
59. 1-receptor down-regulation in heart failure. Circ. Res. 1986 59 : 297 309.
60. 2-adrenoceptors in human heart: Properties, function and alterations in chronic heart failure. Pharmacol. Rev. 1991 43 : 203 42.
61. 4-adrenoceptor mediated responses occur in parallel in a rat model of cardiac failure. Br. J. Pharmacol. 1999 128 : 1399 406.
62. Segrave R, Nathan PJ. Pindolol augmentation of selective serotonin reuptake inhibitors. Accounting for the variability of results of placebo-controlled double-blind studies in patients with major depression. Hum. Psychopharmacol. Clin. Exp. 2005 20 : 163 74.
63. Man in't Veld AJ, Schalekamp MADH. Pindolol acts as beta-adrenoceptor agonist in orthostatic hypotension: Therapeutic implications. BMJ 1981 282 : 929 31.
64. Iskos D, Dutton J, Scheinman MM, Lurie KG. Usefulness of pindolol in neurocardiogenic syncope. Am. J. Cardiol. 1998 82 : 1121 4.
65. Benditt DG, Fahy GJ, Lurie KG, Sakaguchi S, Fabian W, Samniah N. Pharmacotherapy of neurally mediated syncope. Circulation 1999 100 : 1242 8.
66. Nair N, Padder FA, Kutalek S, Kantharia BK. Usefulness of pindolol for treatment of neurocardiogenic syncope. Am. J. Cardiol. 2004 94 : 1189 91.
67. Small KM, McGraw DW, Liggett SB. Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu. Rev. Pharmacol. Toxicol. 2003 43 : 381 411.
68. 2c-adrenergic receptors and the risk of congestive heart failure. N. Engl. J. Med. 2002 347 : 1135 42.
69. 1-adrenergic receptor associated with survival in patients with heart failure. Eur. Heart J. 2000 21 : 1853 8.
70. Forleo C, Resta N, Sorrentino S et al. Association of β-adrenergic receptor polymorphisms and progression to heart failure in patients with idiopathic dilated cardiomyopathy. Am. J. Med. 2004 117 : 451 8.
71. 1-adrenoceptor gene and evaluation of its role in idiopathic dilated cardiomyopathy. J. Mol. Cell. Cardiol. 1999 31 : 1025 32.
72. Colucci WS, Packer M, Bristow MR et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation 1996 94 : 2800 6.
73. Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N. Engl. J. Med. 1996 23 : 1349 55.
74. Packer M, Coats AJ, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 2001 344 : 1651 8.
75. Waagstein F, Bristow MR, Swedberg K et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993 342 : 1441 6.
76. MERIT-HF Study Group. Effect of metoprolol CF/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999 353 : 2001 7.
77. CIBIS-II, Investigators Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): A randomised trial. Lancet 1999 353 : 9 13.
78. 1-adrenergic receptor. J. Biol. Chem. 1999 274 : 12 670 4.
79. 1-adrenoceptors. Br. J. Pharmacol. 2004 142 : 51 6.
80. 1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure. Proc. Natl Acad. Sci. USA 2006 103 : 11 288 93.
81. 1- Adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat. Med. 2003 9 : 1300 5.